Albireo Pharma (ALBO) Misses Q1 EPS by 7c, Revenues Miss

Albireo Pharma (NASDAQ: ALBO) reported Q1 EPS of ($1.39), $0.07 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $970 thousand.

“For Albireo, 2019 is focused on advancing toward potential approval and launch of odevixibat in its first indication, while further developing odevixibat into a pediatric cholestasis medicine that could benefit people across multiple rare diseases,” said Ron Cooper, President and Chief Executive Officer of Albireo. “In the first quarter, we continued to make significant progress on both fronts. While we anticipate PEDFIC 1 topline results at the end of this year or early 2020, we are pleased to expand the PEDFIC program to generate data on additional patient types. We also are extremely excited to be preparing for a pivotal trial with odevixibat in biliary atresia, building on promising results from our Phase 2 trial. In addition, our NASH program is gaining momentum, as we prepare to begin a Phase 2 trial in NAFLD/NASH with elobixibat this quarter.”

For earnings history and earnings-related data on Albireo Pharma (ALBO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Z Squared outlines AI power strategy and Paradox Data acquisition
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c